lasofoxifene has been researched along with palbociclib in 1 studies
| Studies (lasofoxifene) | Trials (lasofoxifene) | Recent Studies (post-2010) (lasofoxifene) | Studies (palbociclib) | Trials (palbociclib) | Recent Studies (post-2010) (palbociclib) |
|---|---|---|---|---|---|
| 88 | 14 | 24 | 911 | 126 | 864 |
| Protein | Taxonomy | lasofoxifene (IC50) | palbociclib (IC50) |
|---|---|---|---|
| Chain B, Cell division protein kinase 6 | Homo sapiens (human) | 0.015 | |
| Chain B, Cell division protein kinase 6 | Homo sapiens (human) | 0.015 | |
| Cyclin-T1 | Homo sapiens (human) | 1.5085 | |
| Cyclin-K | Homo sapiens (human) | 1.207 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 9.8 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.0109 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 9.8 | |
| Cyclin-A2 | Homo sapiens (human) | 2.2042 | |
| Acetylcholinesterase | Mus musculus (house mouse) | 0.021 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.0115 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 9.15 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 4.1887 | |
| G1/S-specific cyclin-D2 | Homo sapiens (human) | 0.0127 | |
| G1/S-specific cyclin-D3 | Homo sapiens (human) | 0.0194 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 3.48 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 1.1821 | |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 0.0631 | |
| Cyclin-dependent kinase 6 | Homo sapiens (human) | 0.018 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, YF; Fanning, SW; Green, B; Greene, GL; Greene, ME; Komm, B; Kurleto, JD; Lainé, M; Phung, L | 1 |
1 other study(ies) available for lasofoxifene and palbociclib
| Article | Year |
|---|---|
Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Models, Animal; Estrogen Receptor alpha; Female; Fulvestrant; Humans; MCF-7 Cells; Mice; Mutation; Neoplasm Metastasis; Piperazines; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Pyridines; Pyrrolidines; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Treatment Outcome | 2021 |